Frequent hemodialysis versus standard hemodialysis for people with kidney failure: Systematic review and meta-analysis of randomized controlled trials.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 22 05 2024
accepted: 19 08 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: epublish

Résumé

Frequent hemodialysis provided more than three times per week may lower mortality and improve health-related quality of life. Yet, the evidence is inconclusive. We evaluated the benefits and harms of frequent hemodialysis in people with kidney failure compared with standard hemodialysis. We performed a systematic review of randomized controlled trials including adults on hemodialysis with highly sensitive searching in MEDLINE, Embase, CENTRAL, and Google Scholar on 3 January 2024. Data were pooled using random-effects meta-analysis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. We adjudicated evidence certainty using GRADE. From 11,142 unique citations, only seven studies involving 518 participants proved eligible. The effects of frequent hemodialysis on physical and mental health were imprecise due to few data. Frequent hemodialysis probably had uncertain effect on death from all cause compared with standard hemodialysis (relative risk 0.79, 95% confidence interval 0.33-1.91, low certainty evidence). Data were not reported for death from cardiovascular causes, major cardiovascular events, fatigue or vascular access. The evidentiary basis for frequent hemodialysis is incomplete due to clinical trials with few or no events reported for mortality and cardiovascular outcome measures and few participants in which patient-reported outcomes including health-related quality of life and symptoms were reported.

Sections du résumé

BACKGROUND BACKGROUND
Frequent hemodialysis provided more than three times per week may lower mortality and improve health-related quality of life. Yet, the evidence is inconclusive. We evaluated the benefits and harms of frequent hemodialysis in people with kidney failure compared with standard hemodialysis.
METHODS METHODS
We performed a systematic review of randomized controlled trials including adults on hemodialysis with highly sensitive searching in MEDLINE, Embase, CENTRAL, and Google Scholar on 3 January 2024. Data were pooled using random-effects meta-analysis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. We adjudicated evidence certainty using GRADE.
RESULTS RESULTS
From 11,142 unique citations, only seven studies involving 518 participants proved eligible. The effects of frequent hemodialysis on physical and mental health were imprecise due to few data. Frequent hemodialysis probably had uncertain effect on death from all cause compared with standard hemodialysis (relative risk 0.79, 95% confidence interval 0.33-1.91, low certainty evidence). Data were not reported for death from cardiovascular causes, major cardiovascular events, fatigue or vascular access.
CONCLUSION CONCLUSIONS
The evidentiary basis for frequent hemodialysis is incomplete due to clinical trials with few or no events reported for mortality and cardiovascular outcome measures and few participants in which patient-reported outcomes including health-related quality of life and symptoms were reported.

Identifiants

pubmed: 39240930
doi: 10.1371/journal.pone.0309773
pii: PONE-D-24-20374
doi:

Types de publication

Journal Article Systematic Review Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0309773

Informations de copyright

Copyright: © 2024 Natale et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Patrizia Natale (P)

Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.
Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J) University of Bari Aldo Moro, Bari, Italy.
Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Suetonia C Green (SC)

Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.

Matthias Rose (M)

Department of Psychosomatic Medicine, Center for Patient-Centered Outcomes Research (CPCOR), Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Michiel L Bots (ML)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Peter J Blankestijn (PJ)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.

Robin W M Vernooij (RWM)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.

Karin Gerittsen (K)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.

Mark Woodward (M)

The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
The George Institute for Global Health, Imperial College, London, United Kingdom.

Carinna Hockham (C)

The George Institute for Global Health, Imperial College, London, United Kingdom.

Krister Cromm (K)

Department of Psychosomatic Medicine, Center for Patient-Centered Outcomes Research (CPCOR), Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Fresenius Medical Care Deutschland GmbH, Global Medical Office, Bad Homburg v.d.H, Germany.

Claudia Barth (C)

B. Braun Avitum AG, Medical Scientific Affairs, Melsungen, Germany.

Andrew Davenport (A)

Department of Nephrology, University College of London, London, United Kingdom.

Jörgen Hegbrant (J)

Division of Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Pantelis Sarafidis (P)

Department of Nephrology, Aristotle University, Hippokration Hospital, Thessaloniki, Greece.

Partha Das (P)

Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.

Christoph Wanner (C)

Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, Würzburg, Germany.
Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Allan R Nissenson (AR)

DaVita International, London, United Kingdom.
David Geffen School of Medicine, University of California Los Angeles, California, Los Angeles, United States of America.

Benedicte Sautenet (B)

Department Nephrologie-Hypertension Arterielle, Dialyses, Transplantation Renale, Tours, France.

Marietta Török (M)

Diaverum Renal Services Group, Budapest, Hungary.

Giovanni Strippoli (G)

Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.
Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J) University of Bari Aldo Moro, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH